Evidence map›Paper›PMID 30026881›Full record

ArticleDisease markers2018

A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.

Teruo Inamoto, Hirofumi Uehara, Yukihiro Akao, Naokazu Ibuki, Kazumasa Komura, Kiyoshi Takahara, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda and 7 more

Abstract read
In one paragraph

Article in Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Non-coding RNA-mediated high expression ofFrontiers in immunology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Teruo InamotoDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.ORCID 0000-0002-1351-1315
Hirofumi UeharaDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Yukihiro AkaoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Naokazu IbukiDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Kazumasa KomuraDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Kiyoshi TakaharaDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Tomoaki TakaiDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Taizo UchimotoDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Kenkichi SaitoDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Naoki TandaDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Yuki YoshikawaDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Koichiro MinamiDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Hajime HiranoDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Hayahito NomiDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
Ryuji KatoCardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan.
Tetsuya HayashiCardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan.
Haruhito AzumaDepartment of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectivesMicroRNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRNAs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict aggressive phenotype from normal nonaggressive counterpart using miRNA expression levels and to assess the prognostic value of this specific miRNA markers in patients with UCB.

methodsTo determine candidate miRNAs as prognostic biomarkers for dividing aggressive type of UCB, miRNA expression was profiled in patients' samples with an aggressive phenotype or nonaggressive phenotype using 3D-Gene miRNA labeling kit (Toray, Japan). To create a prognostic index model, we used the panel of 9-miRNA signature based on Cancer Genome Atlas (TCGA) data portal (TCGA Data Portal (https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp)). miRNA expression data and corresponding clinical data, including outcome and staging information of 84 UCB patients, were obtained. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups.

resultsDeregulation of nine miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, and hsa-miR-33b-3p) was determined in UCB patients with aggressive phenotype compared with nonaggressive subject. To validate the prognostic power of the nine-signature miRNAs using the TCGA dataset of bladder cancer, the survival status and tumor miRNA expression of all 84 TCGA UCB patients were ranked according to the prognostic score values. Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p). Patients with the high-risk miRNA signature exhibited poorer OS than patients expressing the low-risk miRNA profile (HR = 7.05,

conclusionsThe miRNA array identified nine dysregulated miRNAs from clinical samples. This panel of nine-miRNA signature provides predictive and prognostic value of patients with UCB.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCarcinomaHumansMaleMicroRNAsSurvival AnalysisTranscriptomeUrinary Bladder NeoplasmsUrotheliumBiomarkers, TumorMicroRNAs

Identifiers

PMID30026881
PMCPMC6031086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.